Add-on Anifrolumab for Residual Mucocutaneous and Systemic Manifestations During Cyclophosphamide Therapy in Severe Neuropsychiatric Lupus: A Case Report.

Authors

Mariko Hoshino, Toshihiko Shiga, Yumi Morimoto, Jinhai Li, Yuji Nozaki, Koji Kinoshita, Shinya Rai

Published in

Modern rheumatology case reports. Sep 29, 2026. Epub Sep 29, 2026.

Abstract

A 29-year-old woman presented with fever, malar rash, and alopecia. Laboratory evaluation demonstrated a high-titre antinuclear antibody of 1:5120, hypocomplementaemia, and positivity for anti-double-stranded DNA and anti-Smith antibodies, leading to a diagnosis of systemic lupus erythematosus. During the clinical course, she developed progressive peripheral neuropathy with inability to walk. Intravenous methylprednisolone pulse therapy and intravenous immunoglobulin were administered, but neurological improvement was limited, and intravenous cyclophosphamide therapy was initiated. Subsequently, she developed central nervous system manifestations of neuropsychiatric systemic lupus erythematosus and received an additional course of intravenous methylprednisolone. Central nervous system manifestations gradually improved during ongoing intravenous cyclophosphamide therapy; however, fever, rash, and alopecia persisted at the time of transfer to our hospital. Because fever persisted despite antibiotic therapy and mucocutaneous manifestations and hypocomplementaemia progressively worsened, residual systemic lupus erythematosus activity was considered clinically relevant. Anifrolumab was initiated on hospital day 28, coinciding with completion of antibiotic therapy. Fever resolved the following day, while the mucocutaneous manifestations and hypocomplementaemia subsequently showed gradual and sustained improvement. No serious infectious or other adverse events were observed after anifrolumab initiation during ongoing intravenous cyclophosphamide therapy. Reports describing add-on anifrolumab during ongoing intravenous cyclophosphamide therapy for severe systemic lupus erythematosus are extremely limited. This case highlights the potential role of anifrolumab as an adjunctive therapy for persistent systemic and mucocutaneous manifestations suggestive of interferon-associated disease activity during ongoing cyclophosphamide-based intensive immunosuppressive treatment.

PMID:
42808589
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.